The alternative oxidase of Candida albicans causes reduced fluconazole susceptibility

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 4, 2009, Pages 764-773

  Yan, Lan ^a   Li, Miaohai ^b   Cao, Yongbing ^a   Gao, Pinghui ^a   Cao, Yingying ^a   Wang, Yan ^a   Jiang, Yuanying ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Alternative pathway; Drug resistance; Mitochondrion; Reactive oxygen species

Indexed keywords

ALTERNATIVE OXIDASE; AMPHOTERICIN B; BENOMYL; CYANIDE; FLUCONAZOLE; FUNGAL PROTEIN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; PYRROLE; REACTIVE OXYGEN METABOLITE; SALICYLHYDROXAMIC ACID; TERBINAFINE; UNCLASSIFIED DRUG;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG POTENTIATION; FUNGAL STRAIN; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CYANIDES; ENZYME ACTIVATORS; ENZYME INHIBITORS; FLUCONAZOLE; GENE DELETION; MICROBIAL SENSITIVITY TESTS; OXIDOREDUCTASES; SALICYLAMIDES;

EID: 70349469372     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp273     Document Type: Article

References (41)

1. Cowen LE, Steinbach WJ. Stress, drugs, and evolution: The role of cellular signaling in fungal drug resistance. Eukaryot Cell 2008; 7: 747-64.
2. Kelly SL, Lamb DC, Kelly DE et al. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett 1997; 400: 80-2.
3. Du W, Coaker M, Sobel JD et al. Shuttle vectors for Candida albicans: Control of plasmid copy number and elevated expression of cloned genes. Curr Genet 2004; 45: 390-8.
4. White TC. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans. Antimicrob Agents Chemother 1997; 41: 1488-94.
5. Sanglard D, Ischer F, Koymans L et al. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 1998; 42: 241-53.
6. Prasad R, Wergifosse PDE, Goffeau A et al. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr Genet 1995; 27: 320-9.
7. Sanglard D, Ischer F, Monod M et al. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 1997; 143: 405-16.
8. Wirsching S, Michel S, Morschhäuser J. Targeted gene disruption in Candida albicans wild-type strains: The role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Mol Microbiol 2000; 36: 856-65.
9. Mukherjee PK, Chandra J, Kuhn DM et al. Mechanism of fluconazole resistance in Candida albicans biofilms: Phase-specific role of efflux pumps and membrane sterols. Infect Immun 2003; 71: 4333-40.
10. Dunkel N, Liu TT, Barker KS et al. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot Cell 2008; 7: 1180-90.
11. Coste AT, Karababa M, Ischer F et al. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell 2004; 3: 1639-52.
12. Coste A, Turner V, Ischer F et al. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 2006; 172: 2139-56.
13. Morschhäuser J, Barker KS, Liu TT et al. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog 2007; 3 e164.
14. Cannon RD, Lamping E, Holmes AR et al. Candida albicans drug resistance another way to cope with stress. Microbiology 2007; 153: 3211-7.
15. Karababa M, Valentino E, Pardini G et al. CRZ1, a target of the calcineurin pathway in Candida albicans. Mol Microbiol 2006; 59 1429-51.
16. Jain P, Akula I, Edlind T. Cyclic AMP signaling pathway modulates susceptibility of Candida species and Saccharomyces cerevisiae to antifungal azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother 2003; 47: 3195-201.
17. Yan L, Zhang JD, Cao YB et al. Proteomic analysis reveals a metabolism shift in a laboratory fluconazole-resistant Candida albicans strain. J Proteome Res 2007; 6: 2248-56.
18. Rubin-Bejerano I, Fraser I, Grisafi P et al. Phagocytosis by neutrophils induces an amino acid deprivation response in Saccharomyces cerevisiae and Candida albicans. Proc Natl Acad Sci USA 2003; 100: 11007-12.
19. Barelle CJ, Priest CL, Maccallum DM et al. Niche-specific regulation of central metabolic pathways in a fungal pathogen. Cell Microbiol 2006; 8: 961-71.
20. Cheng S, Clancy CJ, Zhang Z et al. Uncoupling of oxidative phosphorylation enables Candida albicans to resist killing by phagocytes and persist in tissue. Cell Microbiol 2007; 9: 492-501.
21. Kontoyiannis DP. Modulation of fluconazole sensitivity by the interaction of mitochondria and Erg3p in Saccharomyces cerevisiae. J Antimicrob Chemother 2000; 46: 191-7.
22. Brun S, Aubry C, Lima O et al. Relationships between respiration and susceptibility to azole antifungals in Candida glabrata. Antimicrob Agents Chemother 2003; 47: 847-53.
23. Brun S, Bergès T, Poupard P et al. Mechanisms of azole resistance in petite mutants of Candida glabrata. Antimicrob Agents Chemother 2004; 48: 1788-96.
24. Chamilos G, Lewis RE, Kontoyiannis DP. Inhibition of Candida parapsilosis mitochondrial respiratory pathways enhances susceptibility to caspofungin. Antimicrob Agents Chemother 2006; 50: 744-7.
25. Geraghty P, Kavanagh K. Disruption of mitochondrial function in Candida albicans leads to reduced cellular ergosterol levels and elevated growth in the presence of amphotericin B. Arch Microbiol 2003; 179: 295-300.
26. Cheng S, Clancy CJ, Nguyen KT et al. A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole. Antimicrob Agents Chemother 2007; 51: 1855-8.
27. Helmerhorst EJ, Murphy MP, Troxler RF et al. Characterization of the mitochondrial respiratory pathways in Candida albicans. Biochim Biophys Acta 2002; 1556: 73-80.
28. Helmerhorst EJ, Stan M, Murphy MP et al. The concomitant expression and availability of conventional and alternative, cyanide-insensitive, respiratory pathways in Candida albicans. Mitochondrion 2005; 5: 200-11.
29. Ruy F, Vercesi AE, Kowaltowski AJ. Inhibition of specific electron transport pathways leads to oxidative stress and decreased Candida albicans proliferation. J Bioenerg Biomembr 2006; 38: 129-35.
30. Huh WK, Kang SO. Molecular cloning and functional expression of alternative oxidase from Candida albicans. J Bacteriol 1999; 181: 4098-102.
31. Huh WK, Kang SO. Characterization of the gene family encoding alternative oxidase from Candida albicans. Biochem J 2001; 356 595-604.
32. Fonzi WA, Irwin MY. Isogenic strain construction and gene mapping in Candida albicans. Genetics 1993; 134: 717-28.
33. Redding S, Smith J, Farinacci G et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: Documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994; 18: 240-2.
34. Petraitiene R, Petraitis V, Groll AH et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12-23.
35. Quan H, Cao YY, Xu Z et al. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole. Antimicrob Agents Chemother 2006; 50: 1096-9.
36. National Committee for Clinical and Laboratory Standards. Methods for Broth Dilution Antifungal Susceptibility Testing of Yeasts, vol. 17, no. 9. Approved Standard (document M27-A). NCCLS, Wayne, PA. 1997.
37. Maxwell DP, Wang Y, McIntosh L. The alternative oxidase lowers mitochondrial reactive oxygen production in plant cells. Proc Natl Acad Sci USA 1999; 96: 8271-6.
38. Kobayashi D, Kondo K, Uehara N et al. Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect. Antimicrob Agents Chemother 2002; 46: 3113-7.
39. Yan L, Zhang J, Li M et al. DNA microarray analysis of fluconazole resistance in a laboratory Candida albicans strain. Acta Biochim Biophys Sin 2008; 40: 1048-60.
40. Suzuki YJ, Forman HJ, Sevanian A. Oxidants as stimulators of signal transduction. Free Radic Biol Med 1997; 22: 269-85.
41. Rognon B, Kozovska Z, Coste AT et al. Identification of promoter elements responsible for the regulation of MDR1 from Candida albicans a major facilitator transporter involved in azole resistance. Microbiology 2006; 152: 3701-22.